MIRA-55 / MIRA Pharma - LARVOL DELTA

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies (ACCESS Newswire) - "The CNS safety findings complement previously reported preclinical efficacy data demonstrating that Mira-55: (i) Reduced pain sensitivity and restored thresholds to near-baseline levels in inflammatory pain models; (ii) Demonstrated morphine-comparable analgesic effects in a validated inflammatory pain model; (iii) Did not produce sedation or opioid-like adverse effects."

Preclinical • CNS Disorders • Inflammation • Pain